Chemomab Therapeutics to Announce Q3 2024 Financial Results and Business Update

TEL AVIV, Israel, Oct. 30, 2024 – Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology company in the clinical stage, is at the forefront of developing advanced treatments for fibro-inflammatory diseases, which are currently areas of high unmet medical need. The company has announced its intention to release its financial results for the third quarter of 2024 and provide a business update on November 14, 2024, at 7:00 am Eastern Time.

Chemomab Therapeutics is pioneering in the development of novel therapeutics aimed at treating fibro-inflammatory conditions. Their research is centered around the biological protein CCL24, which is known to play a critical role in the progression of fibrosis and inflammation. Utilizing this knowledge, Chemomab has created CM-101, a unique monoclonal antibody that effectively neutralizes CCL24. This therapeutic approach has shown promising results in altering disease progression.

In both clinical and preclinical evaluations, CM-101 has exhibited a favorable safety profile and has been well-tolerated by patients. The therapeutic potential of CM-101 extends across a range of severe and life-threatening fibro-inflammatory diseases. Chemomab has conducted four clinical trials, which have yielded positive outcomes for CM-101 in various patient groups.

One of the significant developments for Chemomab is the recent data from its Phase 2 SPRING trial, focusing on primary sclerosing cholangitis (PSC), a rare liver disease. The results have been promising and have set the stage for two critical milestones expected in early 2025. These include receiving feedback from the FDA regarding the design of the Phase 3 registrational trial for PSC and obtaining data from the open-label extension of the SPRING trial. CM-101 has also been granted Orphan Drug and Fast Track designations by the FDA and EMA for its application in treating PSC.

Additionally, Chemomab's CM-101 program is geared towards systemic sclerosis, with the project being ready for Phase 2 trials and having an open Investigational New Drug (IND) application in the U.S. This progress underscores the company's commitment to addressing serious medical conditions through innovative therapeutic solutions.

Chemomab welcomes investors and stakeholders to discuss the financial results and business updates following the release of their press announcement. The company continues to prioritize the advancement of its therapeutic programs and remains dedicated to improving patient outcomes for those suffering from fibro-inflammatory diseases.